| pubmed-article:17664328 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17664328 | lifeskim:mentions | umls-concept:C0043474 | lld:lifeskim |
| pubmed-article:17664328 | lifeskim:mentions | umls-concept:C0205653 | lld:lifeskim |
| pubmed-article:17664328 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:17664328 | lifeskim:mentions | umls-concept:C0178719 | lld:lifeskim |
| pubmed-article:17664328 | lifeskim:mentions | umls-concept:C0209738 | lld:lifeskim |
| pubmed-article:17664328 | lifeskim:mentions | umls-concept:C0585361 | lld:lifeskim |
| pubmed-article:17664328 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:17664328 | pubmed:dateCreated | 2007-9-24 | lld:pubmed |
| pubmed-article:17664328 | pubmed:abstractText | Zidovudine (ZDV) and lamivudine (3TC) metabolism to triphosphates (TP) is necessary for antiviral activity. The aims of this study were to compare ZDV-TP and 3TC-TP concentrations in adolescents receiving twice daily (BID) and once daily (QD) regimens and to determine the metabolite concentrations of ZDV and 3TC during chronic therapy on a QD regimen. Human immunodeficiency virus-infected patients (12 to 24 years) taking ZDV (600 mg/day) and 3TC (300 mg/day) as part of a highly active antiretroviral therapy regimen received QD and BID regimens of ZDV and 3TC for 7 to 14 days in a crossover design. Serial blood samples were obtained over 24 h on the QD regimen. Intracellular mono-, di-, and triphosphates for ZDV and 3TC were measured. The median ratio of BID/QD for ZDV-TP predose concentrations was 1.28 (95% confidence interval [CI] = 1.00 to 2.45) and for 3TC-TP was 1.12 (95% CI = 0.81 to 1.96). The typical population estimated half-lives (+/- the standard error of the mean) were 9.1 +/- 0.859 h for ZDV-TP and 17.7 +/- 2.8 h for 3TC-TP. Most patients had detectable levels of the TP of ZDV (24 of 27) and 3TC (24 of 25) 24 h after dosing, and half-lives on a QD regimen were similar to previously reported values when the drugs were given BID. Lower, but not significantly different, concentrations of ZDV-TP were demonstrated in the QD regimen compared to the BID regimen (P = 0.056). Although findings were similar between the BID and QD groups, the lower concentrations of ZDV and the number of patients below the level of detection after 24 h suggests that ZDV should continue to be administered BID. | lld:pubmed |
| pubmed-article:17664328 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17664328 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17664328 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17664328 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17664328 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:17664328 | pubmed:issn | 0066-4804 | lld:pubmed |
| pubmed-article:17664328 | pubmed:author | pubmed-author:LindseyJane... | lld:pubmed |
| pubmed-article:17664328 | pubmed:author | pubmed-author:McNamaraJames... | lld:pubmed |
| pubmed-article:17664328 | pubmed:author | pubmed-author:CapparelliEdm... | lld:pubmed |
| pubmed-article:17664328 | pubmed:author | pubmed-author:FlynnPatricia... | lld:pubmed |
| pubmed-article:17664328 | pubmed:author | pubmed-author:KnappKatherin... | lld:pubmed |
| pubmed-article:17664328 | pubmed:author | pubmed-author:RodriguezJose... | lld:pubmed |
| pubmed-article:17664328 | pubmed:author | pubmed-author:MartinezJaime... | lld:pubmed |
| pubmed-article:17664328 | pubmed:author | pubmed-author:SerchuckLesli... | lld:pubmed |
| pubmed-article:17664328 | pubmed:author | pubmed-author:HeckmanBarbar... | lld:pubmed |
| pubmed-article:17664328 | pubmed:author | pubmed-author:RodmanJohnJ | lld:pubmed |
| pubmed-article:17664328 | pubmed:author | pubmed-author:RobbinsBrianB | lld:pubmed |
| pubmed-article:17664328 | pubmed:author | pubmed-author:PACTG P1012... | lld:pubmed |
| pubmed-article:17664328 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17664328 | pubmed:volume | 51 | lld:pubmed |
| pubmed-article:17664328 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17664328 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17664328 | pubmed:pagination | 3516-22 | lld:pubmed |
| pubmed-article:17664328 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:17664328 | pubmed:meshHeading | pubmed-meshheading:17664328... | lld:pubmed |
| pubmed-article:17664328 | pubmed:meshHeading | pubmed-meshheading:17664328... | lld:pubmed |
| pubmed-article:17664328 | pubmed:meshHeading | pubmed-meshheading:17664328... | lld:pubmed |
| pubmed-article:17664328 | pubmed:meshHeading | pubmed-meshheading:17664328... | lld:pubmed |
| pubmed-article:17664328 | pubmed:meshHeading | pubmed-meshheading:17664328... | lld:pubmed |
| pubmed-article:17664328 | pubmed:meshHeading | pubmed-meshheading:17664328... | lld:pubmed |
| pubmed-article:17664328 | pubmed:meshHeading | pubmed-meshheading:17664328... | lld:pubmed |
| pubmed-article:17664328 | pubmed:meshHeading | pubmed-meshheading:17664328... | lld:pubmed |
| pubmed-article:17664328 | pubmed:meshHeading | pubmed-meshheading:17664328... | lld:pubmed |
| pubmed-article:17664328 | pubmed:meshHeading | pubmed-meshheading:17664328... | lld:pubmed |
| pubmed-article:17664328 | pubmed:meshHeading | pubmed-meshheading:17664328... | lld:pubmed |
| pubmed-article:17664328 | pubmed:meshHeading | pubmed-meshheading:17664328... | lld:pubmed |
| pubmed-article:17664328 | pubmed:meshHeading | pubmed-meshheading:17664328... | lld:pubmed |
| pubmed-article:17664328 | pubmed:meshHeading | pubmed-meshheading:17664328... | lld:pubmed |
| pubmed-article:17664328 | pubmed:meshHeading | pubmed-meshheading:17664328... | lld:pubmed |
| pubmed-article:17664328 | pubmed:meshHeading | pubmed-meshheading:17664328... | lld:pubmed |
| pubmed-article:17664328 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17664328 | pubmed:articleTitle | Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. | lld:pubmed |
| pubmed-article:17664328 | pubmed:affiliation | Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN 38105, USA. pat.flynn@stjude.org | lld:pubmed |
| pubmed-article:17664328 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17664328 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:17664328 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:17664328 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:17664328 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| pubmed-article:17664328 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:17664328 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17664328 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17664328 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17664328 | lld:pubmed |
